Table 4.
Screen-out by Sex for 2 Trial Characteristics
| Sex Difference in Screen-out | Screen-outs/Total Screened | ||||
|---|---|---|---|---|---|
| Trial Characteristic | Percentage Points | 95% CI | Women | Men | P a |
| Overall | 2.4 | (−.30, +5.2) | 567/2033 | 2304/8711 | |
| Research domains | .01 (0.07*) | ||||
| ART optimization (11 trials) | 3.8 | (+1.6, +6.0) | 301/1442 | 1065/5669 | |
| Inflammation (8 trials) | −6.3 | (−13.3, +.7) | 120/209 | 595/1046 | |
| End-organ diseases (4 trials) | 5.3 | (−4.2, +14.8) | 39/100 | 258/810 | |
| Coinfections and malignancies (2 trials) | 7.6 | (−1.1, +16.2) | 72/152 | 280/702 | |
| Viral hepatitis (3 trials) | 8.2 | (−1.0, +17.4) | 33/114 | 81/378 | |
| Cure (2 trials) | −23.0 | (−38.0, −.08) | 0/12 | 20/89 | |
| Neurology (1 trial) | 26.5 | (−26.5, +79.5) | 2/4 | 4/17 | |
| Type of hemoglobin eligibility criterion | .01 (0.16*) | ||||
| One criterion for all participants (21 trials) | 4.1 | (+2.0, +6.1) | 445/1753 | 1800/7655 | |
| Sex-specific criteria (8 trials) | −1.1 | (−12.7, +10.5) | 113/237 | 470/957 | |
| No minimum eligibility requirement (2 trials) | −14.2 | (−29.4, +1.0) | 9/43 | 34/99 |
Abbreviation: ART, antiretroviral therapy.
aCovariate P values from F test with Knapp-Hartung modification (df = k-1, 31-k) where k = number of levels of covariate. *Adjusted P value includes both covariates in a single model and Monte-Carlo permutation test with 10 000 permutations.